Galapagos begins Phase l trial of GLPG2451 to treat cystic fibrosis

Belgium-based, clinical-stage, biotechnology company Galapagos has begun a Phase l trial of GLPG2451 potentiator to treat cystic fibrosis (CF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news